Research Analysts Set Expectations for AGIO Q3 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Analysts at Zacks Research lifted their Q3 2026 earnings per share (EPS) estimates for Agios Pharmaceuticals in a note issued to investors on Thursday, August 20th. Zacks Research analyst Team now expects that the biopharmaceutical company will earn ($1.79) per share for the quarter, up from their previous estimate of ($1.85). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($5.80) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.77) EPS, FY2026 earnings at ($6.94) EPS, Q3 2027 earnings at ($1.51) EPS, Q4 2027 earnings at ($1.44) EPS, Q1 2028 earnings at ($1.23) EPS, Q2 2028 earnings at ($1.05) EPS and FY2028 earnings at ($3.88) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The company had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.

Other research analysts also recently issued research reports about the stock. Truist Financial dropped their price objective on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. JPMorgan Chase & Co. boosted their price target on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. HC Wainwright boosted their price target on Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, Bank of America upped their price target on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.25.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock opened at $33.90 on Monday. The company has a market cap of $2.02 billion, a PE ratio of -4.84 and a beta of 0.58. The firm has a fifty day moving average price of $35.89 and a two-hundred day moving average price of $31.51. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the transaction, the insider directly owned 54,645 shares in the company, valued at $1,665,579.60. The trade was a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Creative Planning boosted its stake in Agios Pharmaceuticals by 2.2% during the 3rd quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock worth $527,000 after acquiring an additional 280 shares during the last quarter. Assetmark Inc. increased its stake in Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 362 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Agios Pharmaceuticals by 0.4% in the second quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock worth $4,393,000 after purchasing an additional 512 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Agios Pharmaceuticals by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 588 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its position in shares of Agios Pharmaceuticals by 3.4% during the third quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock worth $796,000 after purchasing an additional 662 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.